SCHEMBL139341

SCHEMBL139341

O=C=NCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
IDO1 P14902 3/20 0.47
TAAR1 Q96RJ0 2/20 0.46
PNMT P11086 2/20 0.44
TSHR P16473 3/20 0.43
SMN1; SMN2 Q16637 2/20 0.42
PYCR1 P32322 1/20 0.42
FDPS P14324 1/20 0.40
SIGMAR1 Q99720 2/20 0.39
CYP3A4 P08684 2/20 0.38
CYP2D6 P10635 2/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
THPO P40225 1/20 0.38
HSD17B10 Q99714 1/20 0.38
POLB P06746 1/20 0.38
IGF1R P08069 1/20 0.38
ALOX15 P16050 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30387398 1.00 MAPK1 (0.47) MAPK1TDP1IDO1TAAR1PNMT
SCHEMBL460729 0.85 MAPK1 (0.36) MAPK1TDP1IDO1TAAR1TSHR
SCHEMBL20263500 0.85 ALDH1A1 (0.41) TAAR1TSHRSMN1; SMN2PYCR1CYP3A4
SCHEMBL29387410 0.85 MAPK1 (0.36) MAPK1TDP1IDO1TAAR1TSHR
SCHEMBL14465785 0.85 S1PR1 (0.37) MAPK1TDP1TAAR1TSHRSMN1; SMN2
SCHEMBL29170709 0.83 MAPK1 (0.36) MAPK1TDP1TAAR1PNMTSLC6A3
SCHEMBL3601103 0.81 PNMT (0.50) MAPK1TDP1IDO1TAAR1PNMT
SCHEMBL31121581 0.80 MIF (0.52) IDO1TAAR1PNMTTSHRSMN1; SMN2
SCHEMBL1457458 0.80 MIF (0.52) IDO1TAAR1PNMTTSHRSMN1; SMN2
SCHEMBL5654790 0.79 IDO1 (0.51) IDO1PYCR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 257 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116533420-A Preparation method of near infrared barrier polyurethane lens 浙江伟星光学股份有限公司 2023-08-04 CN claimed
CN-116042168-A High-viscosity quick UV (ultraviolet) curing adhesive and preparation method thereof 安徽大学 2023-05-02 CN claimed
EP-4713378-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2026-03-25 EP disclosed
EP-3774961-B1 ADDUCTS OF AMINE CATALYSTS FOR PRODUCING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2025-01-15 EP disclosed
WO-2024236000-A1 ESTERIFIED ETHANOLAMINES FOR PREPARING ISOCYANURATE POLYMERS COVESTRO DEUTSCHLAND AG (DE) 2024-11-21 WO disclosed
EP-4464727-A1 ESTERIFIED ETHANOLAMINES FOR THE PREPARATION OF ISOCYANURATE POLYMERS Covestro Deutschland AG (DE) 2024-11-20 EP disclosed
CN-118084739-A Continuous preparation method and device of diuron 江苏快达农化股份有限公司 2024-05-28 CN disclosed
US-20240150515-A1 Low Viscosity Catalyst Compositions for Producing Isocyanurate Polymers COVESTRO DEUTSCHLAND AG (DE) 2024-05-09 US disclosed
US-11919854-B2 P2RX7 modulators in therapy CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2024-03-05 US disclosed
CN-117551001-A Preparation method and preparation system of substituted phenyl isocyanate 湖南化工研究院有限公司 2024-02-13 CN disclosed
CN-117362576-A Aqueous polyurethane urea dispersions 科思创知识产权两合公司 2024-01-09 CN disclosed
US-20030158198-A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBVIE INC. 2003-08-21 US disclosed
US-20030158188-A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor ABBOTT LABORATORIES 2003-08-21 US disclosed
US-6506761-B1 Compound of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: CORVAS INTERNATIONAL, INC. 2003-01-14 US disclosed
US-6506760-B1 Compounds of the invention are active as inhibitors of Thrombin and are useful in treating disease states in mammals which are characterized by abnormal thrombosis and have the following structure: CORVAS INTERNATIONAL, INC. 2003-01-14 US disclosed
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors HARTER WILLIAM GLEN (US) 2003-01-02 US disclosed
WO-2002083627-A2 LIGANDS DES INTEGRINS AVSS6 MERCK PATENT GMBH (DE) 2002-10-24 WO disclosed
WO-2002064599-A1 BICYCLIC PYRIMIDINE MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
WO-2002064598-A1 THIENO'2,3-D PYRIMIDINDIONE DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY LLC (US) 2002-08-22 WO disclosed
US-6362342-B1 BIOSYNTHESIS; DRUG LIBRARIES LION BIOSCIENCE AG (DE) 2002-03-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030004172-A1 Fused pyrimidinone matrix metalloproteinase inhibitors MMP13, MMP3, MMP25 MAPK1 1365/4885TDP1 2109/4885IDO1 325/4885
US-20030158198-A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor TRPV1, VIPR1, TMEM109 MAPK1 306/4885TDP1 3013/4885IDO1 1232/4885
US-11919854-B2 P2RX7 modulators in therapy P2RX7, P2RX2, P2RX1 MAPK1 1830/4885TDP1 2519/4885IDO1 1389/4885
US-20030158188-A1 Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor TRPV1, TMEM109, VIPR1 MAPK1 370/4885TDP1 3067/4885IDO1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.